Compare S&P Global Inc (SPGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? S&P Global Inc trades at $406.37 (market cap $118.72B), while Vertex Pharmaceuticals Incorporated trades at $510.07 (market cap $127.55B). The key difference: S&P Global Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and S&P Global Inc pays a 0.96% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SPGI | VRTX | |
|---|---|---|
Market Cap | $118.72B | $127.55B |
Volume | 1,647,917 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $517.92 | $557.96 |
52-Week Low | $370.42 | $407.37 |
Typical Hold Time | 123 Days | 120 Days |
Enterprise Value | $130.21B | $121.68B |
Dividend Yield | 0.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $406.06, up 2.75% today, with strong analyst support (85.7% buy ratings) and a consensus price target of $509.50. The stock shows robust fundamentals, including 30.54% net income margin and consistent revenue growth, though technical indicators signal near-term bearish pressure. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives, positioning the company for future revenue streams.
Outlook remains positive due to high profitability, strategic acquisitions, and dominant market position, but risks include competitive pressures and macroeconomic sensitivity. The stock offers upside based on analyst targets, supported by stable cash flows and dividend payments, making it a compelling hold for long-term investors despite technical headwinds.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
